天天摸夜夜摸成人免费视频-天天摸夜添狠狠添高-天天摸天天做天天爽-天天摸天天做-国产成人啪午夜精品网站男同-国产成人女人在线视频观看

您好!歡迎訪問上海起發實驗試劑有限公司網站!
全國服務咨詢熱線:

15921799099

當前位置:首頁 > 資料下載 > BioCheck新產品BC-1301 說明書

BioCheck新產品BC-1301 說明書

發布時間:2017/7/31      點擊次數:1001

世界*實驗材料供應商 BioCheck正式授權上海起發為其中國代理, BioCheck在一直是行業的*,一直為廣大科研客戶提供zui為的產品和服務,上海起發一直秉承為中國科研客戶帶來的產品,的服務,簽約 BioCheck就是為了給廣大科研客戶帶來更加完善的產品和服務,您的滿意將是我們zui大的收獲

 BioCheck中國代理, BioCheck上海代理, BioCheck北京代理,BioCheck廣東代理, BioCheck江蘇代理BioCheck湖北代理,BioCheck天津,BioCheck黑龍江代理,BioCheck內蒙古代理,BioCheck吉林代理,BioCheck福建代理, BioCheck江蘇代理, BioCheck浙江代理, BioCheck四川代理

BIOCHECK公司由創始人 Dr. John Chen, Medix創立, 是一家抓也提供腫瘤標志物,心肌標志物,激素類zui高性價比的抗體的公司。
  

簡要原理

利用競爭酶聯免疫方法,預先在微孔中包被羊抗兔抗體,實驗時先后加入氯霉素標準品或待測樣本,氯霉素酶標抗原和兔抗氯霉素抗體。經過室溫溫育,反應液中的兔抗氯霉素抗體與微孔板上的羊抗兔抗體結合,待測樣品中的抗原與氯霉素酶標抗原競爭微孔板上的兔抗氯霉素抗體。洗滌后,沒有與抗

體結合的待測樣品中的抗原或酶標抗原被洗去,再加入反應底物,結合的酶標抗原的酶將底物轉化為藍色產物,加入終止液后顏色由藍色變為黃色。反應完成后,樣品中氯霉素含量越多,反應呈色就越淺;反之,樣品中氯霉素含量越少,則呈色越深。利用標準曲線可計算出樣品中氯霉素含量。

技術參數

   檢測蜂蜜、蛋類、牛奶、奶粉、水產品、動物組織(肌肉、肝臟等)、飼料、血清、血漿及尿液樣本中存在的氯霉素,定量限可達0.025 ppb。

No.

樣品

檢測下限

1

蜂蜜

0.02 ppb (0.02 ng/g)

2

蛋類

0.02 ppb (0.02 ng/g)

3

牛奶

0.002 ppb (0.002 ng/ml)

4

奶粉

0.012 ppb (0.012 ng/g)

5

蝦,魚及肉類

0.08 ppb (0.08 ng/g)

6

飼料

0.08 ppb (0.08 ng/g)

7

血清/血漿

0.02 ppb (0.02 ng/ml)

8

尿液

0.04 ppb (0.04 ng/ml)

 

交叉反應

名稱

百分比

氯霉素堿

0.4%

甲基氯霉素

<0.04%

 

回收率                                        

No.

樣品

回收率

1

蜂蜜

70% ~ 110%

2

牛奶

90% ~ 130%

3

蛋,蝦,魚及肉類

95% ~ 120%

4

飼料

95% ~ 120%

5

血清 / 血漿

90% ~ 120%

6

尿液

100% ~ 130%

 

PD-1 ENZYME IMMUNOASSAY TEST KIT

Catalog Number: BC-1301

Enzyme Immunoassay for the Quantitative Determination of PD- 1 Concentration in Human Serum and Plasma

 

FOR RESEARCH USE ONLY

Not for use in diagnostic procedures

INTRODUCTION

Programmed cell death protein 1, (PD-1, CD279, PDCD1), is a cell surface receptor that is critical for the regulation of T cell inflammatory activity and maintains peripheral tolerance in the immune system (1). With an extracellular IgV domain, a transmembrane domain, and an intracellular tail with two phosphorylation sites (SHP-1 and SHP-2), PD- 1 is able to interact with ligands PD-L1 and PD-L2 to down-regulate the immune system and suppress T cell activity (2). Upon antigen recognition, an activated T cell expresses PD-1 on its surface and produces interferons, which induces expression of PD-L1, thereby promoting apoptosis or cell death. (3) However when hijacked by tumor cells, aberrant expression of PD-1 ligands inhibits immune-modulatory T cell activation, leading to disease progression (4).

Elevated levels of PD-1 in serum and plasma have been associated with rheumatoid arthritis and skin sclerosis (5,6). Also, PD-1 is predominantly expressed by tumor infiltrating T cells(7). Further research implies that using monoclonal antibodies to target the PD-1 immunologic checkpoint has contributed to breakthrough progress in understanding and treating cancers such as melanoma and other various non-small cell lung cancer (4).

PRINCIPLE OF THE ASSAY

The PD-1 ELISA is based on the principle of a solid phase enzyme-linked immunosorbent assay. The assay system utilizes a unique monoclonal antibody pair directed against a distinct antigenic determinant on the PD-1 molecule. One mouse monoclonal anti- PD- 1 antibody is used for solid phase immobilization (on the microtiter wells). Another mouse monoclonal anti-PD-1 antibody conjugated to horseradish peroxidase (HRP) is in the enzyme conjugate solution. The test samples are allowed to react sequentially with the two antibodies, resulting in the PD-1 molecules to be sandwiched between the solid phase and enzyme-linked antibodies. After two separate 60- minute incubation steps at room temperature, the wells are rinsed with Wash Buffer to remove unbound labeled antibodies. TMB Reagent is added and incubated

for 30 minutes under dark conditions, resulting in the development of a blue color. The color development is stopped with the addition of Stop Solution, changing the color to yellow. The concentration of PD-1 is directly proportional to the color intensity of the test samples. Absorbance is measured spectrophotometrically at 450 nm.

REAGENTS AND MATERIALS PROVIDED

  • Antibody-Coated Wells (1 plate, 96 wells)

Microtiter wells coated with mouse monoclonal anti-PD-1

  • 50 ng/ml PD-1 Standard (0.5 mL /vial)

50 ng/mL PD-1 in phosphate buffer-BSA solution with preservatives

3. Standard and Sample Diluent (30 mL/bottle, 1 bottle)

Contains phosphate buffer-BSA solution with preservatives

  • Enzyme Conjugate Reagent (12 mL/vial, 1 vial)

Contains mouse monoclonal anti-PD-1 conjugated to horseradish peroxidase

  • 20X Wash Buffer (50 mL/bottle, 1 bottle) Phosphate buffer with detergents
  • TMB Reagent (11 mL/bottle, 1 bottle)

Contains one-step TMB solution

  • Stop Solution (11 mL/bottle, 1 bottle)

Contains diluted hydrochloric acid (1N HCl)

 

STORAGE CONDITIONS

  • Store the unopened kit at 2-8°C upon receipt and when it is not in use, until the expiration shown on the kit label. Refer to the package label for the expiration date.
  • Keep microtiter plate in a sealed bag with desiccant to minimize exposure to damp air.

 

REAGENT PREPARATION

  • All reagents should be allowed to reach room temperature (18-25°C) before use.
  • For each test run, prepare a fresh standard set.
  • Dilute 50 ng/mL to 10 ng/mL with Standard/Sample diluent. Prepare two-fold serial dilutions of the 10 ng/mL Standard with Standard/Sample Diluent:
  • 10 ng/mL: 0.12 mL of 50 ng/mL + 0.48 mL of Standard/Sample Diluent
  • 5 ng/mL: 0.25 mL of 10 ng/mL+ 0.25 mL of Standard/Sample Diluent
  • 2.5 ng/mL: 0.25 mL of 5 ng/mL+ 0.25 mL of Standard /Sample Diluent
  • 1.25 ng/mL: 0.25 mL of 2.5 ng/ml + 0.25 mL of Standard/Sample Diluent
  • 0.625 ng/mL: 0.25 mL of 1.25 ng/mL + 0.25 mL of Standard/Sample Diluent
  • 0.313 ng/mL: 0.25 mL of 0.625 ng/mL + 0.25 mL of Standard/Sample Diluent
  • 0.156 ng/mL: 0.25 mL of 0.313 ng/mL + 0.25 mL of Standard Diluent
  • 0 ng/mL: 0.25 mL of Standard Diluent
  • Patient samples need to be diluted 4-fold prior to use. Prepare a series of small tubes (i.e., 1.5 mL microcentrifuge tubes) and mix 60 µL of serum with 180 µLStandard/Sample Diluent.
  • Working Wash Buffer: Preparation of 1X Wash Buffer from 20X Stock. Add 50 mL of 20X Wash Buffer Stock to 950 mL of DI H2O. The Working Wash Buffer is stable at 2-8°C for 30 days. NOTE: Any crystals that may be present due to high salt concentration must be redissolved at room temperature before making the dilution.

 

ASSAY PROCEDURE

  • Prepare Standards. See Reagent Preparation.
  • Dilute samples 1:4 dilution. See Reagent Preparation.
  • Secure the desired number of coated wells in the holder.
  • Dispense 100 mL of PD-1 standards, and DILUTED specimens into the appropriate wells.
  • Incubate for 60 minutes at room temperature (18-25 °C).
  • Remove incubation mixture by flicking plate contents into a waste container. Rinse and flick the microtiter wells 5 times with 300 m L Working Wash Buffer. Strike the wells onto absorbent paper or paper towels to remove all residual water droplets.
  • Dispense 100 mL of PD-1 Working Enzyme Conjugate Reagent into each well.
  • Incubate for 60 minutes at room temperature (18-25 °C).
  • Remove incubation mixture by flicking plate contents into a waste container. Rinse and flick the microtiter wells 5 times with 300 uL Working Wash Buffer. Strike the wells onto absorbent paper or paper towels to remove all residual water droplets.
  • Dispense 100 mL TMB solution into each well.
  • Incubate for 30 minutes at room temperature (18-25 °C).
  • Stop the reaction by adding 100 mL of Stop Solution into each well.
  • Gently mix for 30 seconds. It is important to make sure that all the blue color changes to yellow color compley.
  • Read absorbance at 450 nm with a microtiter well reader within 15 minutes.

CALCULATION OF RESULTS

  • Calculate the mean absorbance value (OD450) for each set of reference standards, controls and samples.
  • Construct a standard curve by plotting the mean absorbance obtained for each reference standard against its concentration in ng/ml on graph paper, with absorbance on the vertical (y) axis and concentration on the horizontal (x) axis.
  • The corresponding concentration of PD-1 (ng/mL) can be determined from the standard curve using the mean absorbance value for each sample. Depending on experience and/or the availability of computer capability, other methods of

data reduction may be employed.

  • The obtained values of the samples should be multiplied by the dilution factor of 4 to obtain PD-1 results in ng/ml.

EXAMPLE OF STANDARD CURVE

Results of a typical standard run with absorbency readings at 450 nm shown on the Y axis against PD -1 concentrations shown on the X axis. NOTE: This standard curve is for the purpose of illustration only, and should not be used to calculate unknowns. Each laboratory must generate its own data and standard curve in each experiment.

 

PD-1

Absorbance

(ng/ml)

(450 nm)

0

0.089

0.156

0.138

0.313

0.190

0.625

0.284

1.25

0.481

2.5

0.851

5

1.581

10

2.776

 

nm

3

 

 

 

 

 

2.5

 

 

 

 

 

(450

 

 

 

 

 

2

 

 

 

 

 

Absorbance

1.5

 

 

 

 

 

1

 

 

 

 

 

0.5

 

 

 

 

 

0

 

 

 

 

 

 

0

2

4

6

8

10

 

 

 

PD-1 Conc. (ng/ml)

 

 

PERFORMANCE CHARACTERISTICS

  • Sensitivity

The minimum detectable concentration of the PD-1 ELISA assay as measured by 2SD from the mean of a zero standard is estimated to be 0.15 ng/ml.

 

  • Precision

 

  • Intra-Assay Precision

Within-run precision was determined by replicate determinations of three different samples in one assay. Within-assay variability is shown below:

 

Sample

1

2

3

# Replicates

24

24

24

Mean PD-1 (ng/mL)

8.4

13.2

22.9

S.D.

0.6

1.0

0.9

C.V. (%)

7.0%

7.2%

3.8%.

 

2

 

  • Inter-Assay Precision

Between-run precision was determined by replicate measurements of three different samples over a series of individually calibrated assays. Between-assay variability is shown below:

 

Sample

1

2

3

# Replicates

20

20

20

Mean PD-1 (ng/mL)

9.1

13.5

25.3

S.D.

0.8

1.1

0.9

C.V. (%)

9.2%

7.9

3.7

 

  • Recovery and Linearity Studies

 

  • Recovery

Samples were spiked with known PD-1 levels and assayed in duplicate. The mean recovery was 105.3%.

PAIR

EXPECTED

OBSERVED

% RECOVERY

NUMBER

[PD-1]

[PD-1]

 

 

(ng/mL)

(ng/mL)

 

1

8

8.8

110.0%

2

12.5

13.1

104.8%

3

25

25.3

101.2%

 

  • Linearity

Three samples were serially diluted to determine linearity. The mean recovery was 99.6%.

 

#

Dilution

Expected

Observed

 

 

 

Conc. (ng/ml)

Conc. (ng/ml)

% Expected

1.

1:2

 

10.1

114.8%

 

1:4

8.8

8.8

N/A

 

1:8

 

7.8

88.6%

 

 

 

 

Mean = 101.7%

 

 

 

 

 

2.

1:2

 

14.5

110.6%

 

1:4

13.1

13.1

N/A

 

1:8

 

11.6

88.5%

 

 

 

 

Mean = 99.6%

3.

1:2

 

26.5

104.7%

 

1:4

25.3

25.3

N/A

 

1:8

 

23.0

90.0%

Mean = 97.4%

REFERENCES

  • Fife, B. T., & Pauken, K. E. (2011). The role of the PD-1 pathway in autoimmunity and peripheral tolerance. Annals of the New York Academy of Sciences, 1217(1), 45-59.
  • Riella, L. V., Paterson, A. M., Sharpe, A. H., & Chandraker, A. (2012). Role of the PD-1 Pathway in the Immune Response. American Journal of Transplantation?: Official Journal of the American Society of

Transplantation and the American Society of Transplant

Surgeons, 12(10), 2575–2587.

  • Zak, Krzysztof & Ki, Rados?aw & Przetocka, Sara & Golik, Przemys?aw & Guzik, Katarzyna & Musielak, Bogdan & Dömling, Alexander & Dubin, Grzegorz & Holak, Tad. (2015). Structure of the Complex of Human Programmed Death 1, PD-1, and Its Ligand PD-L1. Structure. 23. . 10.1016/j.str.2015.09.010.
  • Zoran Gatalica, Carrie Snyder, Todd Maney, Anatole Ghazalpour, Daniel Holterman, Nianqing Xiao, Peggy Overberg, Inga Rose, Gargi D. Basu, Semir Vranic, Henry T. Lynch, Daniel D. Von Hoff and Omid Hamid. Programmed Cell Death 1 (PD-1) and Its Ligand (PD-L1) in Common Cancers and Their Correlation with Molecular Cancer Type.

Cancer Epidemiol Biomarkers Prev. December 1 2014 (23) (12) 2965-2970.

  • Greisen, S., Rasmussen, T., Stengaard-Pedersen, K., Hetland, M., Hørslev-Petersen, K., Hvid, M., & Deleuran, B. (2013). Increased

soluble programmed death-1 (sPD-1) is associated with disease activity and radiographic progression in early rheumatoid arthritis. Scandinavian Journal of Rheumatology,43(2), 101-108.

  • Yanaba, K., Hayashi, M., Yoshihara, Y., & Nakagawa, H. (2016). Serum levels of soluble programmed death-1 and programmed death ligand-1 in systemic sclerosis: Association with extent of skin sclerosis. The Journal of Dermatology,43(8), 954-957.
  • Ahmadzadeh, M., Johnson, L. A., Heemskerk, B., Wunderlich, J. R., Dudley, M. E., White, D. E., & Rosenberg, S. A. (2009). Tumor antigen–specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood, 114(8), 1537–1544.

 

部分產品報價如下:

貨號品名規格價格品牌
BC-1009AFP EIA Kitkit3980 BioCheck
BC-1011CEA EIA Kitkit4016 BioCheck
BC-1013CA 125 EIA Kitkit4970 BioCheck
BC-1015CA 15-3 EIA Kitkit4970 BioCheck
BC-1017CA 19-9 EIA Kitkit4970 BioCheck
BC-1019PSA EIA Kit*kit3962 BioCheck
BC-1021Free PSA EIA Kit*kit4196 BioCheck
BC-1023Free b-hCG EIA Kitkit4196 BioCheck
BC-1061b-2 Microglobulin EIA Kit §kit4250 BioCheck
BC-1001TSH EIA Kit §kit3800 BioCheck
BC-1003U-TSH (S-TSH) EIA Kit §kit3800 BioCheck
BC-1005T3 EIA Kit §kit3656 BioCheck
BC-1006Free T3 EIA Kit §kit3890 BioCheck
BC-1007T4 EIA Kit §kit3656 BioCheck
BC-1008Free T4 EIA Kitkit3890 BioCheck
BC-1081Rubella IgG EIA Kit*kit4106 BioCheck
BC-1083Rubella IgM EIA Kit*kit4196 BioCheck
BC-1085Toxo IgG EIA Kit*kit3980 BioCheck
BC-1087Toxo IgM EIA Kit*kit4070 BioCheck
BC-1089CMV IgG EIA Kit*kit3980 BioCheck
BC-1091CMV IgM EIA Kit*kit4070 BioCheck
BC-1093HSV I IgG EIA Kitkit3980 BioCheck
BC-1095HSV I IgM EIA Kitkit4196 BioCheck
BC-1097HSV II IgG EIA Kitkit3980 BioCheck
BC-1099HSV II IgM EIA Kitkit4070 BioCheck
BC-1051H. pylori IgG (Qualitative) EIA Kitkit4016 BioCheck
BC-1052H. pylori IgG (Quantitative) EIA Kitkit4106 BioCheck
BC-1053H. pylori IgM (Qualitative) EIA Kitkit4286 BioCheck
BC-1027hCG EIA Kit §kit3800 BioCheck
BC-1029FSH EIA Kit §kit3800 BioCheck
BC-1031LH EIA Kit §kit3800 BioCheck
BC-1037Prolactin EIA Kit §kit3800 BioCheck
BC-1025Human Ferritin EIA Kit §kit3800 BioCheck
BC-1033HGH EIA Kit §kit3800 BioCheck
BC-1035IgE EIA Kit §kit3800 BioCheck
BC-1203Adiponectin EIA Kit*kit7580 BioCheck
BC-1105Troponin I EIA Kit §kit5330 BioCheck
BC-1117Myoglobin EIA Kit §kit4250 BioCheck
BC-1119HS-CRP EIA Kit §kit4250 BioCheck
BC-1121CK-MB EIA Kit*kit6680 BioCheck
BC-1129MPO EIA Kit*kit8480 BioCheck
BC-1111Estradiol EIA Kit §kit4250 BioCheck
BC-1113Progesterone EIA Kit §kit4250 BioCheck
BC-1115Testosterone EIA Kit §kit4250 BioCheck

 

我們公司zui大優勢是強大的采購,
1:基本什么都能進口,血清,抗體,耗材,還有部分限制進口的,
2 貨品全,現經營過700多個品牌,基本所有生物試劑耗材都可以進口,特別是冷偏的產品那就更有優勢,
3:提供加急服務,一般1-2周到貨,超過時限加急費全免
4:價格公道,絕大部分價格有優勢,當然不能保證100%產品都有價格優勢,
5:良好的信譽,大部分客戶我們提供貨到付款服務,客戶包括清華,北大 交大 復旦,中山等100多所大學,ROCHE,阿斯利康,國藥fisher500多家公司
6:我們還是santa,Advanced Biotechnologies Inc;Athens Research & Technology, bangs, BBInternational, crystalchem, dianova, FD Neurotechnologies, Inc. FormuMax Scientific, Inc; Genebridege; Glycotope Biotechnology GmbH; iduron; Innovative Research of America Ludger  neuroprobe; omicronbio; Polysciences; prospecbi; QA-BIOquickzymeRESEARCH DIETS, INCsterlitechsysyTriLink BioTechnologies, IncBIOCHECKINC -biochem;zyagen;......幾十家國外公司授權代理
7:我們還從事invitrogenqiagen; abcam ;sigma;neb; roche;merck; rnd; BD; GE; pierce; BioLegend....等*批發            


文件下載    
上海起發實驗試劑有限公司
地址:上海浦東川沙鎮川沙路6619號上海起發實驗試劑有限公司
郵箱:xs1@78bio.com
傳真:021-50724961
關注我們
歡迎您關注我們的微信公眾號了解更多信息:
歡迎您關注我們的微信公眾號
了解更多信息
主站蜘蛛池模板: 日韩不卡一区| 国产精品一级| 欧美精品三区| 成人国产第一区在线观看| 欧美 亚洲 中文字幕| 四虎一区二区三区精品| 欧美在线精品一区二区三区| 久久精品久久久久| 在线看看| 四虎成人影视| 99色这里只有精品| 天天操天天操天天操天天操| 99热都是精品| 成人三级在线观看| 最刺激黄a大片免费观看下截| 欧美亚洲日本在线| 黄在线观看免费| 额去鲁在线视频| 日韩欧美在线观看| h片视频在线观看| 日韩欧美亚洲综合一区二区| 午夜影院免费看| 精品91一区二区三区| 99热成人精品免费久久| 久久久久久免费一区二区三区| 在线观看www视频| 国内精品视频在线观看| 亚洲精品高清在线观看| 从指尖传出的| 久久99精品福利久久久| 欧美成人午夜视频免看| 欧美日韩综合网在线观看| 99视频在线观看免费视频| 国产精品青草久久久久福利99| 日韩欧美一区二区三区不卡| 国产成人精品曰本亚洲| 白浆免费视频国产精品视频| 成 人 黄 色 视频免费下载| 成人毛片基地| 狠狠干人人干| 欧美午夜精品一区二区三区|